topside, as well-as those associated with various parameters in the ship contamination model, are addressed in the uncertainty analysis. The analysis of radiation exposure to the crew also requires estimation of radiation intensities below deck (due to fallout) and the apportionment in time of crew activities below and on deck. A ship-shielding factor is defined as the ratio of intensity below to the mean intensity topside. This factor, previously determined for each type of ship of interest in References 3, 4, 5 and 6, is roughly 0.1 and is nearly constant over the usual crew locations within a ship. Variations in this value, due primarily to different main deck thicknesses, are treated as an uncertainty in Section 4. Specific durations of topside exposure are given in ship logs for shot day (rarely thereafter) when the radiological situation altered the normal pattern of duties. For other days, and when unspecified, the topside intervals are taken to be 0800-1200, 1330-1700, and 1800-2000 hours, which amount to 40 percent of a day. é The mean film badge dose to the crew is obtained from time integration of intensity for all intervals below (including the shielding factor) and on deck; a conversion factor is used to account for body shielding by the badge wearer (Reference 7). To facilitate the calculation, the daily fractional topside duration, rather than’each specified interval, is used on the third and subsequent days after burst, when the lower intensity lessens the need for such precision in timing. Because the specified intervals are nearly centered around midday, this approximation is suitable by the third day. Day-by-day and cumulative film badge doses to the average crewman of each ship are calculated and presented in Section 3. Calculations are continued through 31 May 1954 when the roll-up phase was drawing to an end. An uncertainty analysis of the dose calculations is provided in Section 4 In Section 5, the available dosimetry records are analyzed and compared with the calculated doses. Conclusions and a total dose summary are presented in Section 6. 15